Brian J. Abraham

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• A Conserved Enhancer Locus in Extrachromosomal DNA and Homogeneously Staining Regions Activates <i>MYC</i> Transcription in Group 3 Medulloblastoma

  Cancer Research · 2026-04-22

• Abstract LB493: A conserved enhancer locus in ecDNA and HSRs activates MYC transcription in group 3 medulloblastoma

  Cancer Research · 2026-04-17

• Abstract 630: Elucidation of PAX3::FOXO1 tumor initiation mechanisms in human induced pluripotent stem cell models.

  Cancer Research · 2026-04-03

• Abstract 4024: Dysregulated AKT signaling reprograms osteosarcoma to drive selective reliance on EP300

  Cancer Research · 2026-04-03

• Abstract 3500: Synergistic targeting of EP300/CBP and EYA co-activators collapses the rhabdomyosarcoma core regulatory circuit

  Cancer Research · 2026-04-03

• Abstract 385: A genome derived non coding reporter of dynamic cancer cell state.

  Cancer Research · 2026-04-03

• Abstract A047: A conserved enhancer locus in ecDNA and HSRs activates <i>MYC</i> transcription in Group 3 Medulloblastoma

  Cancer Research · 2026-03-23

• 3D-super-enhancers are condensate-associated <i>cis</i> -regulatory communities

  Nucleic Acids Research · 2026-02-24 · 2 citations

• Abstract IA001: Mechanism of PAX3::FOXO1 establishment of alveolar rhabdomyosarcoma cell state in human tumor initiation

  Cancer Research · 2026-01-13

• Abstract A020: Insights into human alveolar rhabdomyosarcoma initiation using a human t(2;13) induced pluripotent stem cell model

  Cancer Research · 2026-01-13

• Generation of an iPSC-derived alveolar rhabdomyosarcoma cell line during directed endothelial differentiation

  Stem Cell Research · 2025-11-14

• Abstract B043: Dysregulated AKT signaling reprograms osteosarcoma to drive selective reliance on EP300

  Cancer Research · 2025-09-25

• Abstract A020-PR004: KAT6A and KAT6B are therapeutic targets to enhance the efficacy of differentiation therapy and GD2 immunotherapy in neuroblastoma

  Cancer Research · 2025-09-25

• Specific oncogene activation of the cell of origin in mucosal melanoma

  Nature Communications · 2025-07-22 · 1 citations

• KAT6A/B inhibition synergizes with retinoic acid and enhances the efficacy of GD2-targeted immunotherapy in neuroblastomaPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-07-02 · 1 citations

• Multitargeted Reduction of Inflammation and Atherosclerosis in <i>Tet2</i> -deficient CHIP via XPO1 Inhibition and Atf3 restorationPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-06-17 · 2 citations

• Abstract 2612: Elucidation of PAX3::FOXO1 initiation mechanisms in human induced pluripotent stem cell models

  Cancer Research · 2025-04-21

• Abstract 2601: KAT6A and B inhibition increases efficacy of differentiation and GD2 targeting immunotherapy in neuroblastoma

  Cancer Research · 2025-04-21

• Abstract A020: Treatment of neuroblastoma with retinoic acid plus a KAT6A/B inhibitor induces sustained growth arrest and increases GD2 expression as a target for immunotherapy

  Cancer Research · 2025-03-11

• Bone morphogenetic protein (BMP) signaling determines neuroblastoma cell fate and sensitivity to retinoic acid

  Nature Communications · 2025-02-28 · 4 citations